Puma Biotechnology (PBYI) Receivables - Net (2016 - 2026)
Puma Biotechnology's (PBYI) quarterly Receivables - Net came in at $26.3 million in Q1 2026, up 2.26% YoY from $25.7 million in Q1 2025, and down 50.93% on a QoQ basis from $53.7 million in Q4 2025.
Puma Biotechnology (PBYI) Receivables - Net (2016 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 11 years of Receivables - Net data on file, last reported at $26.3 million in Q1 2026.
- Quarterly Receivables - Net rose 2.26% year-over-year to $26.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.3 million (up 2.26% YoY) and the FY2025 annual result came in at $53.7 million, up 67.61% from the prior year.
- Receivables - Net slipped to $26.3 million in Q1 2026, from $53.7 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $55.4 million in Q3 2024 to a low of $25.6 million in Q1 2024.
- A 5-year average of $33.9 million and a median of $31.2 million in 2023 frame the typical range for Receivables - Net.
- Annual changes were most pronounced in 2024 — Receivables - Net soared 91.22% — and 2025, when it sank 39.42%.
- Tracing PBYI's Receivables - Net over 5 years: stood at $40.4 million in 2022, then grew by 18.56% to $47.8 million in 2023, then sank by 33.08% to $32.0 million in 2024, then surged by 67.61% to $53.7 million in 2025, then sank by 50.93% to $26.3 million in 2026.
- The last three Receivables - Net figures came in at $26.3 million (Q1 2026), $53.7 million (Q4 2025), and $33.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.06 Mn |
| Jun 30, 2026 | 34.06 Mn |
| Mar 31, 2026 | 26.33 Mn |
| Mar 31, 2026 | 26.33 Mn |
| Dec 31, 2025 | 53.65 Mn |
| Dec 31, 2025 | 53.65 Mn |
| Sep 30, 2025 | 33.57 Mn |
| Sep 30, 2025 | 33.57 Mn |
| Jun 30, 2025 | 26.12 Mn |
| Jun 30, 2025 | 26.12 Mn |
| Mar 31, 2025 | 25.75 Mn |
| Mar 31, 2025 | 25.75 Mn |
| Dec 31, 2024 | 32.01 Mn |
| Dec 31, 2024 | 32.01 Mn |
| Sep 30, 2024 | 55.40 Mn |
| Sep 30, 2024 | 55.40 Mn |
| Jun 30, 2024 | 28.91 Mn |
| Jun 30, 2024 | 28.91 Mn |
| Mar 31, 2024 | 25.57 Mn |
| Mar 31, 2024 | 25.57 Mn |